External validation of the UKPDS risk engine in incident type 2 diabetes: A need for new type 2 diabetes-specific risk equations

Diabetes Care

Volumn 37, Issue 2, 2014, Pages 537-545

  Bannister, Christian A ^a   Poole, Chris D ^a   Jenkins Jones, Sara ^b   Ll Morgan, Christopher ^a   Elwyn, Glyn ^a   Spasíc, Irena ^a   Currie, Craig J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Global Epidemiology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; UK PROSPECTIVE DIABETES STUDY RISK ENGINE; VALIDATION PROCESS; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; MIDDLE AGED; RISK FACTOR; UNITED KINGDOM; VALIDATION STUDY;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84893102408     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1159     Document Type: Article

References (40)

1. Rydén L, Standl E, BartnikM, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
2. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes national clinical guideline for management in primary and secondary care (update) [Internet], 2008. London, Royal College of Physicians. Available from www.nice.org.uk/nicemedia/pdf/G66diabetesfullguideline.pdf. Accessed 11 April 2012
3. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society TSA. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl. 5):v1-v52
4. Department of Health. Putting Prevention First - Vascular Checks: Risk Assessment and Management. London, Department of Health, 2008
5. National Institute for Health and Clinical Excellence. Lipid Modification : Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease [Internet], 2008. London, NICE. Accessed 17 April 2012
6. Van Dieren S, Beulens JWJ, Kengne AP, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012;98:360-369
7. UK Prospective Diabetes Study (UKPDS). 8. Study design, progress and performance. Diabetologia 1991;34:877-890
8. Kothari V. UKPDS 60: Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33: 1776-1781
9. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-679
10. IDF Clinical Guidelines Task Force. Global Guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23:579-593
11. Canadian Diabetes Association. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2008;32(Suppl. 1):S1-S201
12. National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk [Internet], 2012. Melbourne, National Stroke Foundation. Available from strokefoundation.com.au/site/media/ AbsoluteCVD-GL-webready.pdf. Accessed 21 December 2012
13. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London, Royal College of Physicians, 2008
14. Whitfield MD, Gillett M, Holmes M, Ogden E. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year periodda pilot study. Public Health 2006;120:1140-1148
15. Dijkstra RF, Niessen LW, Braspenning JC, Adang E, Grol, RT. Patient-centred and professional-directed implementation strategies for diabetes guidelines: a clusterrandomized trial-based cost-effectiveness analysis. Diabet Med 2006;23:164-170
16. Glümer C, Yuyun M, Griffin S, et al.What determines the cost-effectiveness of diabetes screening? Diabetologia 2006;49:1536-1544
17. Adler AI. UKPDSdmodelling of cardiovascular risk assessment and lifetime simulation of outcomes. Diabetic Med 2008;25(Suppl. 2):41-46
18. Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009;52:2001-2014
19. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med 2005;22:554-562
20. Jimeno Mollet J, Molist Brunet N, Franch Nadal J, Serrano Borraz V, Serrano Barrag'an L, Gracia Gim'enez R. Variability in the calculation of coronary risk in type-2 diabetes mellitus. Aten Primaria 2005;35: 30-36 [in Spanish]
21. Stephens JW, Ambler G, Vallance P, Betteridge DJ, Humphries SE, Hurel SJ. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil 2004;11:521-528
22. Yang X, So W-Y, Kong APS, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 2008;101: 596-601
23. Kengne A, Patel A, Colagiuri S, Heller S. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 2010;53:821-831
24. Pellegrini E, Maurantonio M, Giannico IM, et al. Risk for cardiovascular events in an Italian population of patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2011; 21:885-892
25. Davis WA, Colagiuri S, Davis TM. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Med J Aust 2009;190:180-184
26. Van Dieren S, Peelen LM, Nöthlings U, et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia 2011;54:264-270
27. Song SH, BrownPM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 2004; 21:238-245
28. Van der Heijden A a W a, Ortegon MM, Niessen LW, Nijpels G, Dekker JM. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. Diabetes Care 2009;32:2094-2098
29. Medicines and Healthcare products Regulatory Agency. Clinical Practice Research Datalink [Internet], 2013. Available from www.cprd.com. Accessed 5 March 2012
30. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14
31. Gallagher AM, Puri S van ST. Linkage of the General Practice Research Database (GPRD) with Other Data Sources. Pharmacoepidemiol Drug Saf 2011;20:S230
32. Department of Health. Health and Social Care Information Centre. Hospital episode statistics [Internet], 2012. Available from www.hscic.gov.uk/hes. Accessed 5 March2012
33. Office for National Statistics. Mortality statistics: Metadata [Internet], 2012. Available from www.ons.gov.uk/ons/guide-method/user-guidance/ health-andlife-events/mortality-metadata.pdf. Accessed 14 March 2013
34. Janssen KJM, Vergouwe Y, Donders AR, et al. Dealing with missing predictor values when applying clinical prediction models. Clin Chem 2009;55:994-1001
35. R Development Core Team. R: a language and environment for statistical computing [Internet], 2011. R Foundation for Statistical Computing. Available from www.r-project.org. Accessed 14 March 2013
36. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013;98: 668-677
37. Hammad TA, McAdams MA, Feight A, Iyasu S, Dal Pan GJ. Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2008;17: 1197-1201
38. Holden SH, Barnett AH, Peters JR, et al. The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010. Diabetes Obes Metab 2013;15:844-852
39. Currie CJ. Gale EA, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med 2010;27: 938-948
40. Itensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853